Actively Recruiting

Age: 50Years - 70Years
All Genders
NCT06452745

Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile

Led by Institut Investigacio Sanitaria Pere Virgili · Updated on 2024-10-02

2000

Participants Needed

2

Research Sites

1093 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Colorectal cancer is the most frequent tumor in our environment if both sexes are considered together. Every year almost 800 cases are diagnosed in the districts of Tarragona. A little more than half of colorectal cancers are cured with surgery, with or without the addition of complementary treatments with chemotherapy and/or radiation therapy. Those who are not cured is because at the time of diagnosis the disease has already spread or they spread after having been treated surgically with curative intent. The purpose of the EarlyCRC project is to determine whether metabolites (substances of low molecular weight) can be found in the urine and stool of patients with colorectal cancer or polyps that can be easily and cheaply differentiated (urine or stool analysis) between the patients affected by colorectal cancer or polyps, from healthy individuals. For the identification of these possible metabolites, the urine analysis will be performed using the usual techniques in metabolomics, which studies the existing metabolites in biological processes.

CONDITIONS

Official Title

Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile

Who Can Participate

Age: 50Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a positive FOBT test result from the Colorectal Cancer Early Detection Program and referred for a colonoscopy.
Not Eligible

You will not qualify if you...

  • Patients diagnosed with another primary neoplasm in the last 5 years, except cervical carcinoma in situ or non-melanoma skin cancer.
  • Patients with severe kidney disease stage IV (creatinine clearance < 30 ml/min).
  • Patients with severe active liver disease (hepatitis, cirrhosis).
  • Refusal to sign informed consent.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Hospital Universitari Sant Joan de Reus

Reus, Tarragona, Spain, 43204

Actively Recruiting

2

Hospital Universitari Joan XXIII

Tarragona, Tarragona, Spain, 43005

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here